PURPOSE: Preclinical studies suggest that inhibition of vascular endothelial growth factor
(VEGF) improves glioma response to radiotherapy. Bevacizumab, a monoclonal antibody …

PURPOSE: Reirradiation is a treatment option for recurrent high-grade glioma with proven
but limited effectiveness. Therapies directed against vascular endothelial growth factor have …

INTRODUCTION: Bevacizumab, a monoclonal antibody against vascular endothelial growth
factor (VEGF), has shown promise in the treatment of patients with recurrent high-grade …

Purpose Virtually all patients with malignant glioma (MG) eventually recur. This study
evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ) …

PURPOSE: Patients with recurrent malignant gliomas treated with stereotactic radiosurgery
(SRS) and multiagent systemic therapies were reviewed to determine the effects of patient …

Surgical resection followed by radiotherapy and temozolomide in newly diagnosed
glioblastoma can prolong survival, but it is not curative. For patients with disease …

Background: Bevacizumab, a humanized monoclonal antibody against vascular endothelial
growth factor, may have activity in recurrent malignant gliomas. At recurrence some patients …

Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth
factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination …

Purpose: Bevacizumab is associated with decreased vascular permeability that allows for
more aggressive radiotherapy schedules. We conducted a phase II trial in newly diagnosed …

Re-irradiation has been shown to be a meaningful option for recurrent high-grade glioma
(HGG) patients. Furthermore, bevacizumab exerts certain activity in combination with …